Eric Jonasch MD

Eric Jonasch, MD, is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. Dr. Jonasch also serves as Director of the Von Hippel–Lindau (VHL) Clinical Center at MD Anderson and Co-Director of the MD Anderson Kidney Cancer Research Program.

Dr. Jonasch earned his medical degree from McGill Medical School in Montreal, Canada and completed his clinical residency in internal medicine at the Royal Victoria Hospital, also located in Montreal. He later completed a clinical fellowship in hematology/oncology at the New England Medical Center and a research fellowship at the Beth Israel Deaconess Medical Center.

Dr. Jonasch’s clinical interests focus on tissue-based translational research in renal cell carcinoma and VHL disease. He heads a number of investigator-initiated clinical trials and ongoing laboratory research efforts in these disease states to evaluate the determinants of response and resistance to targeted therapies.

Dr. Jonasch is a member of multiple professional organizations, including the American Association for Cancer Research, the American Society of Clinical Oncology. He also serves as a reviewer for numerous journals, including The New England Journal of Medicine, Journal of Clinical Oncology, Journal of Clinical Investigation, and Cancer Research. He has authored or co-authored more than 200 peer-reviewed journal articles and numerous book chapters. He is editor of the textbook Kidney Cancer, Principles and Practice.

Dr. Jonasch currently serves as Vice Chair of the NCCN Kidney Cancer Panel.